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Interleukin-8 delays spontaneous and tumor necrosis factor-a-medi-
ated apoptosis of human neutrophils. During inflammation, polymorpho-
nuclear neutrophils (PMN) are exposed to and influenced by various
cytokines, including the chemoattractant interleukin-8 (IL-8). We tested
the hypothesis that IL-8 affects apoptosis in PMN. We investigated which
IL-8 receptor (RI or RII) might be involved, as well as the role of Bcl-2.
Human PMN were isolated and cultured up to 30 hours. Apoptosis was
detected by UV and light microscopy, as well as by DNA-fragmentation
assay, and quantitated by flow cytometry. Interleukin-8 significantly de-
layed spontaneous apoptosis at 10, 20, and 30 hours in a dose-dependent
fashion. Polymorphonuclear neutrophil treatment with the highest con-
centration of IL-8 (100 nM) decreased the percentage of apoptotic cells
from 2.1 6 1.5 to 0.8 6 0.2 after 10 hours, from 31 6 14 to 8 6 5 after 20
hours, and from 47 6 15 to 18 6 8 after 30 hours of incubation (P , 0.05
for all time points, N 5 6). Interleukin-8 also inhibited TNFa-mediated
PMN apoptosis. Incubation with 20 ng/ml TNFa resulted in 23 6 6%
apoptotic cells at four hours, whereas pretreatment with IL-8 (50 nM)
decreased this percentage to 11 6 3 (N 5 5, P , 0.05). We next studied
the role of both types of IL-8 receptors, RI and RII, by comparing the
effect of IL-8 and the product of growth-related oncogene alpha (Groa)
on PMN cultured for 20 hours. Both IL-8 and Groa attenuated apoptosis,
although IL-8 was more effective than Groa. Bcl-2 was detected by
intracellular fluorescent antibody cell sorter analysis, Western blot, and
reverse transcription-polymerase chain reaction (RT-PCR). Neither rest-
ing PMN nor IL-8-treated neutrophils expressed BCL-2 protein, which
was readily detected in control cells. Furthermore, we could not detect
BCL-2 gene expression by RT-PCR. We conclude that IL-8 prolongs the
lifespan of human neutrophils in vitro by delaying apoptosis. This effect
may be important for a controlled and effective inflammatory response.
The delay in apoptosis can be mediated by the IL-8 RII, while RI may
provide an added effect. The actions of IL-8 on apoptosis are Bcl-2
independent.
Polymorphonuclear neutrophils (PMN) play an important role
in a variety of inflammatory renal diseases. Activated PMN
respond with release of reactive oxygen species, degranulation of
tissue degrading enzymes, and phagocytosis [1–4]. The acute
process is self-limiting. Pathological conditions, such as impaired
function or decreased PMN number, may result in life-threaten-
ing diseases. Apoptosis is an important regulator of cell turnover.
Several diseases result from abnormalities in apoptosis [5]. Che-
motaxis is a mechanism through which PMN are recruited to sites
of inflammation, and it is mediated by several substances includ-
ing chemokines [6–9]. The chemokine a-family targets mainly
PMN. Members of this family are all about 70 to 80 amino acids
in size and contain four conserved cysteines. The first two
cysteines are separated by one variable amino acid (CXC). After
the discovery of neutrophil-activating peptide 1, which is identical
to interleukin-8 (IL-8), more than 12 other family members have
been described including the growth-related oncogene alpha
(Groa). Polymorphonuclear neutrophils express high numbers of
two CXC cytokine receptor types, namely IL-8 RI and IL-8 RII.
The latter is characterized by a high affinity for all members of the
a-chemokine family including Groa, whereas IL-8 RI has high
affinity for only IL-8 [10–12]. Interleukin-8 was initially classified
according to its chemotactic effect on PMN; however, additional
biological functions of IL-8 have been described. Whether or not
IL-8 also modulates apoptosis is unclear. Apoptotic PMN have a
decreased capability to respond to activating stimuli, such as
FMLP or opsonized zymosan [13] and are swiftly removed by
phagocytosis [14]. Thus, studies on regulation of PMN apoptosis
are relevant and may provide information with therapeutic impli-
cations. We investigated the effect of IL-8 on spontaneous
apoptosis in PMN and on rapidly-occurring tumor necrosis factor
(TNFa)-mediated apoptosis. We studied the relative participation
of IL-8 RI and IL-8 RII in this process, and investigated changes
in the expression of Bcl-2. Our data suggest that IL-8 is indeed
important in regulating PMN apoptosis.
METHODS
Reagents
The following reagents were purchased from Sigma (St. Louis,
MO, USA or Dreisenhofen, Germany): propidium iodide (PI),
Ficoll-Hypaque, bovine serum albumin (BSA), DNase-free
RNase, modified Wright Giemsa, 49,6 diamidino-2-phenylindole
(DAPI), and sulforhodamin 101 (SR 101). Recombinant IL-8 and
recombinant TNFa were obtained from Genzyme (Rüsselsheim,
Germany), and recombinant Groa from Laboserve (Giessen,
Germany). All antibodies were purchased from Dako (Hamburg,
Germany): murine monoclonal anti-human Bcl-2-antibody (clone
124), mouse IgG1 negative control as isotype control (generated
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against Aspergillus niger glucose oxidase, an enzyme that is irrel-
evant for mammalian cells), and FITC-conjugated F(ab9)2 frag-
ment of goat anti-mouse immunoglobulin as secondary antibody.
Human polymorphonuclear neutrophil isolation, cell count
determination and cell viability
Polymorphonuclear neutrophils were prepared from hepa-
rinized whole blood of healthy donors. The isolation protocol
included red blood cell sedimentation by Plasmagel (Cellular
Products Inc., Buffalo, NY, USA) followed by Ficoll-Hypaque
density gradient centrifugation, and hypotonic red cell lysis. Cells
were resuspended at 107/ml in RPMI 1640 supplemented with 2
mM glutamine and penicillin/streptomycin. Trypan blue exclusion
was used to determine cell viability. Ten microliters of PMN in
suspension were incubated with 40 ml Trypan blue (Seromed,
Berlin, Germany) for five minutes at room temperature. Cells
were counted in duplicate using a hemocytometer and considered
viable if able to exclude Trypan blue.
Culture conditions of human polymorphonuclear neutrophils
A total of 250 ml PMN at 107/ml RPMI without fetal calf serum
(FCS) were pipetted into 12 3 75 mm polypropylene culture tubes
(Fisher, Fair Lawn, NJ, USA). Then 210 ml of supplemented
RPMI 1640 containing 20% heat-inactivated FCS together with
IL-8, or Groa, or an equal volume of carrier protein containing
PBS-solution without cytokines (0.5% BSA), was added giving a
final concentration of 5 3 106 cells per ml. Cell suspensions were
incubated at 37°C in 5% CO2 for up to 30 hours. In another set of
experiments we tested the effect of IL-8 on TNFa-mediated
apoptosis. Cells were cultured as described above except that IL-8
(100 nM) or an equal volume of carrier was added before PMN
were challenged with TNFa (20 ng/ml). We checked all solutions
and reagents used in cell culture for the presence of endotoxin;
the solutions contained less than 0.05 ng/ml endotoxin as demon-
strated by a Limulus amoebocyte lysate assay (Biowhittaker,
Walkersville, MD, USA). All experiments were done in duplicate.
Wright Giemsa, 4*,6 diamidino-2-phenylindole, and
Sulforhodamin 101 cell staining
Cytocentrifuge cell preparations were either stained using
modified Wright Giemsa stain or were fixed in 70% ethanol and
stained with a solution containing 1 mg/ml 49,6 diamidino-2-
phenylindole (DAPI). Morphologic features of apoptosis, as
described by Kerr, Whyte and Haslet [15] including pyknotic
nuclei, nuclear and cytoplasmic condensation, and the formation
of apoptotic bodies, were considered as evidence for apoptosis.
DNA fragmentation assay
DNA fragmentation was studied using isolated low molecular
weight DNA. A total of 5 3 106 PMN were resuspended in lysis
buffer (0.5 mM Tris-HCl, pH 7.5, 20 mM EDTA, pH 8.0, 0.5%
Triton X-100) and the lysate was centrifuged at 20,000 3 g for 20
minutes at 4°C to select the low molecular weight DNA. Super-
natants were extracted twice with an equal volume of PCIA
(Tris-saturated phenol:chloroform:isoamyl alcohol at 25:24:1) and
twice with CIA (chloroform:isoamyl alcohol at 24:1). DNA was
precipitated at 220°C overnight by adding 2.2 volumes of absolute
ethanol in the presence of 0.3 M sodium acetate pH 5.2. DNA was
centrifuged at 13,500 g for 20 minutes at 4°C, air dried and
resuspended in TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0)
containing RNase Plus (5 Prime-3 Prime). After a 30 minute
incubation at 37°C, DNA was quantitated and 7.5 mg were
electrophoresed in an 1.5% agarose gel containing 0.5 mg/ml
ethidium bromide. Gels were visualized under UV light.
Apoptosis measurements with propidium iodide-stained
polymorphonuclear neutrophils and flow cytometry
Flow cytometry was used to measure DNA content at the single
cell level as described previously [16]. The method is based on the
fact that endonuclease activation generates low molecular weight
DNA fragments in apoptotic cells. After membrane permeabili-
zation, these fragments leak out resulting in decreased DNA-
content in apoptotic cells, while the DNA content in non-
apoptotic cells remains unchanged. Briefly, freshly isolated or
cultured cells were spun at 200 3 g for five minutes at 4°C and
carefully resuspended in PBS containing 0.5 mM EDTA. Chilled
95% ethanol was added to a final concentration of 70% and the
cell mixtures were stored at 220°C for one to two days. The PMN
were pelleted (200 g, 5 min, 4°C) and resuspended in 250 ml
PBS/0.5 mM EDTA/1% BSA; 250 ml PBS containing 200 mg
DNase-free RNase and 500 ml PBS containing 50 mg propidium
iodide were added. Cells were held for 15 minutes in the dark at
room temperature and then stored at 4°C for six to eight hours in
the staining mixture allowing low molecular DNA fragments to
leave permeabilized cells. PMN were analyzed using a fluorescent
antibody cell sorter (FACscan; Becton Dickinson, Heidelberg,
Germany) and 10,000 events per sample were collected in list-
mode using Lysis II software for data acquisition and analysis.
Western blot analysis
Cell lysates were prepared by resuspending 5 3 106 cells in 500
ml of ice-cold lysing solution (40 mM Tris-HCl, pH 8.0, containing
276 mM NaCl, 2% NP 40, 20 mg/ml leupeptin, 2 mM PMSF, 20
mg/ml aprotinin, 4 mM EDTA, and 20% glycerol). Samples were
stored for 30 minutes on ice and centrifuged at 12,000 3 g for two
minutes. Supernatant was recovered and protein concentration
was estimated by BCA protein assay (Pierce, Rockford, IL, USA).
Samples were incubated for five minutes at 95°C in loading buffer
(250 mM Tris-HCl, pH 6.8 with 4% SDS, 20% glycerol, 0.01%
bromphenol blue) and 20 mg protein per lane were loaded on
12.5% sodium dodecyl sulfate (SDS)-polyacrylamide gel, electro-
pheresed, and blotted onto polyvinylidene difluoride membrane
by a semi-dry technique. Bcl-2 was detected using a monoclonal
antibody to human Bcl-2 oncoprotein (4 mg/ml) and an alkaline
phosphatase-labeled goat anti-mouse IgG (1:10,000; Boehringer
Mannheim, Germany). The blot was developed by incubation in a
chemiluminescence substrate (Tropix, Bedford, MA, USA) and
exposed to a x-ray film.
Flow cytometry analysis of intracellular Bcl-2 protein
Freshly isolated or cultured PMN or U937 were stained with
Trypan blue. Cell count and viability was assessed using a
hemocytometer. Then, 106 cells were pelleted (200 g, 5 min, 4°C)
and resuspended in 250 ml of 4% paraformaldehyde in PBS. Cells
were stored on ice for 20 minutes, washed once in PBS plus 1%
BSA (buffer A) and resuspended in 100 ml permeabilization
buffer containing PBS, 1% BSA, and 0.2% Saponin (buffer B).
Monoclonal antibody to Bcl-2 (8 mg/ml), or an equal amount of
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mouse IgG1 negative control (isotype control) or PBS only was
added and samples were kept for 30 minutes on ice. Cells were
washed and incubated with 10 mg FITC-conjugated F(ab9)2
fragment of goat anti-mouse immunoglobulin in 110 ml of buffer
A. After washing, cells were resuspended in 500 ml of buffer A,
and stored on ice in the dark until analyzed using a FACScan flow
cytometer equipped with lysis II software. Antibody concentra-
tions were based on results of preliminary titration experiments.
Each experiment included a sample for measurement of autofluo-
rescence and fluorescence caused by secondary antibody alone.
RNA extraction and RT-PCR
RNA was purified by resuspending 5 3 106 to 1 3 107 PMN or
control HL-60 cells in 1 ml RNA-STAT 60 (Tel-Test “B”, Inc.,
Friendswood, TX, USA) following the Tel-Test “B” procedure,
wherein the RNA/RNA-STAT mixture is extracted with chloro-
form, the RNA precipitated with isopropanol, and dissolved in 1
mM EDTA, pH 8.0. Gene-specific RNA was analyzed by RT-PCR
using 1 mg of RNA per reaction. First strand cDNA for two
independent RNA samples and PCR (performed in triplicate)
were prepared as described in the Clontech (Palo Alto, CA, USA)
1 st-Strand cDNA Synthesis and RT-PCR kits. Five microliters of
cDNA were used per 50 ml PCR reaction and cycling conditions
were 94°C for 45 seconds, 58°C for one minute and 72°C for two
minutes for 30 cycles using a GeneAmp PCR System 9600 (Perkin
Elmer, Norwalk, CT, USA). Glyceraldehyde-3-phosphate dehy-
drogenase (G3PDH) primers (Clontech) were used as an internal
control.
Primers for Bcl-2 were selected using the MacVector (Kodak)
primer pair program and included 59-GCCTTCTTTGAGTTCG-
GTGGG-39 and 59-GAGCAGAGTCTTCAGAGACAGCCAG-
39. The primers were synthesized using an Applied Biosystems
Model 394 DNA synthesizer by the University of North Carolina
Pathology Department Oligonucleotide Synthesis Facility. PCR
products were electrophoresed in 1.8% Metaphor (FMC Bio-
Products, Rockland, ME, USA) agarose gels in TBE (Tris pH 8.0,
89 mM borate and 2 mM EDTA) buffer, stained in 0.5 mg/ml
ethidium bromide and photographed. A control reaction was run
on at least one sample from each RNA preparation with PCR of
samples without reverse transcriptase to assess contamination by
genomic DNA. No bands were seen in these lanes (data not
shown).
Statistical analysis
Statistical analysis was performed on a Macintosh computer
(Apple Inc., Cupertino, CA, USA) equipped with commercially
available program (Statview, Cricket Software Inc., Philadelphia,
PA, USA). The nonparametric signed Wilcoxon rank test was
used to compare results between paired groups to test if the
differences were unequal to 0. Differences were considered to be
significant when the P value was , 0.05.
RESULTS
To determine the involvement of IL-8 in the regulation of
neutrophil apoptosis, the effect of IL-8 on cultured PMN was
studied in six independent experiments, each using cells from a
single donor preparation. Cells were cultured with or without IL-8
at concentrations ranging from 1 to 100 nM. Samples were
harvested at 10, 20, and 30 hours and the percentage of apoptotic
PMN was assessed by flow cytometry. The FACs results showed
that IL-8 treatment caused a dose- and time-dependent delay of
spontaneous apoptosis (Fig. 1). A significant reduction in the
percentage of apoptotic PMN was observed as early as 10 hours
after cells were cultured with the highest cytokine concentration
of 100 nM (mean of the difference of the pairs: 21.6%). All IL-8
concentrations were significant after 20 hours (100 nM, 224.2%;
50 nM, 219.6%; 10 nM, 211.3%; 5 nM, 26.3%; 1 nM, 23.2%). At
30 hours all concentrations save the lowest (1 nM) remained
significant (100 nM, 229.3%; 50 nM, 226.5%; 10 nM, 210.4%; 5
nM, 27.6%). No significant cell loss was observed up to 30 hours
and cell viability exceeded 92%, as determined by Trypan blue
exclusion (data not shown). No significant cell loss was observed
up to 30 hours and cell viability exceeded 92%, as determined by
Trypan blue exclusion (data not shown).
Polymorphonuclear neutrophils cultured for 20 hours devel-
oped morphological signs of apoptosis, including pyknotic nuclei,
nuclear condensation, and formation of apoptotic bodies, as
identified by staining with DAPI (Fig. 2) or with modified Wright
Giemsa (data not shown). Morphological features of apoptosis
were clearly inhibited in samples treated with 100 nM IL-8 for 20
hours (Fig. 2). Also, IL-8 diminished DNA-fragmentation, a
hallmark of apoptosis. Low molecular weight DNA isolated from
5 3 106 PMN was electrophoresed on agarose gels. Extensive
DNA “laddering” was observed, when cells were cultured for 20
hours without IL-8. In contrast, IL-8 treatment diminished the
occurrence of typically fragmented low molecular DNA (Fig. 3).
Since our earlier work had shown that TNFa treatment accel-
erated PMN apoptosis [16], it was of particular interest to
determine if IL-8 specific regulation of apoptosis could, in fact,
override TNFa-mediated pathways. We stimulated PMNs to
apoptosis with TNFa (20 ng/ml). For this set of experiments we
concentrated on the four-hour time point, since we knew from
earlier studies that the TNF effect plateaus at that time [16].
Interleukin-8 (50 nM) pretreatment significantly diminished apo-
ptosis (23 6 6 to 11 6 23, N 5 5; Fig. 4).
In PMN, stimulation of the IL-8 RI and RII generates a greater
Fig. 1. Apoptosis was measured in freshly isolated polymorphonuclear
neutrophils (PMN) and in samples cultured for 10 hours, 20 hours, and
30 hours in the absence (bold line) or in the presence of interleukin-8
(IL-8). Cells were treated with IL-8 at 1 nM (l), 5 nM (Œ), 10 nM (f), 50
nM (*), or 100 nM (F). Neutrophils (PMN) from the same donor
preparation was used in each experiment to assure compatible conditions
(N 5 6). Data are depicted as mean 6 SEM. Significant inhibition (P ,
0.05) was found for incubation with the following IL-8 concentrations: at
10 hours $ 50 nM, at 20 hours for all concentrations, at 30 hours $ 5 nM.
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biochemical response than binding to IL-8 RII only [17, 18]. To
determine the relative effects of the two IL-8 receptors on PMN
apoptosis we compared the effect of IL-8 and Groa in parallel.
Based on the experiments shown in Figure 1, the 20-hour time
point was selected. Using flow cytometry, five different concen-
trations of each chemokine were tested in seven independent
experiments. The results demonstrated that both agents were
capable of mediating a delay in PMN apoptosis compared to
controls (Fig. 5). The difference compared to untreated control
cells was significant for IL-8 at all concentrations and for Groa
at $ 5 nM. At 50 nM and 100 nM, IL-8 inhibited apoptosis
significantly more than Groa (mean of the difference of the pairs:
23.9% for 50 nM; 26.4% for 100 nM). We tested for the possibility
of an additive effect of both cytokines in two separate experi-
ments. The percentage of apoptotic PMN was 30% for untreated
samples, 21% for 10 nM IL-8, 21% for 10 nM Groa, and 20% for
the combination of 10 nM IL-8 and 10 nM Groa. The results
demonstrate no additive effect of IL-8 and Groa on PMN
apoptosis. We chose this cytokine concentration, since it gave half
of the maximal inhibitory effect without causing a stronger IL-8
effect.
To investigate possible mechanisms involved in IL-8-mediated
cell rescue, we next tested whether or not IL-8 delayed PMN
apoptosis by inducing Bcl-2 production. Using FACs analysis
Bcl-2 protein was not detectable in freshly isolated PMN, as well
as in PMN that were cultured for 24 hours in the presence or in
the absence of IL-8 (100 nM; N 5 3), whereas Bcl-2 was readily
detectable in the U 937 cells, which were used as a positive control
(data not shown). Neither freshly isolated PMN nor PMN that
were cultured for 24 hours with or without IL-8 (100 nM)
expressed detectable Bcl-2 protein levels as determined by West-
ern blotting (data not shown). In contrast, Bcl-2 was clearly
measurable in the monocytic cell line U937. To test for gene
expression, we assayed for Bcl-2 mRNA by RT-PCR. Two inde-
pendent experiments were performed. No measurable up-regula-
tion of Bcl-2 mRNA by IL-8 treatment was observed (Fig. 6). The
promyelocytic cell line HL-60 served as a positive control.
DISCUSSION
Our results indicate that the prototype chemokine IL-8 affects
programmed cell death of human PMN in vitro, resulting in a
delay of spontaneous as well as TNFa-mediated apoptosis. We
used the fact that PMN undergo apoptosis when placed in culture
to demonstrate that the inhibitory effect of IL-8 on spontaneous
PMN apoptosis occurs in a dose- and time-dependent fashion. We
also provide evidence that both types of IL-8 receptors play a role
in regulating apoptosis. Groa, which binds only RII, was effective
compared to controls, while IL-8, which binds both RI and RII,
was more effective than Groa. Thus, the delay in apoptosis can be
mediated by RII in any event, while additional binding to RI may
provide an added effect. Several genes have been characterized
Fig. 2. Polymorphonuclear neutrophils (PMN) were cultured for 20 hours in the absence (A) and in the presence of 100 nM interleukin-8 (IL-8) (B).
Cells were stained in DAPI and photographs were taken using an UV-filter. A representative image shows that IL-8 treatment prevented typical findings
of apoptosis, such as pyknotic nuclei, chromatin condensation, and nuclear fragmentation.
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that regulate apoptosis, including the Bcl family [19]. Polymor-
phonuclear neutrophils do not generally express the apoptosis-
delaying Bcl-2 gene. We wondered whether or not IL-8 could
inhibit apoptosis by inducing expression of Bcl-2. Our findings
indicate that no such up-regulation occurs, as shown both at the
protein and mRNA levels.
Polymorphonuclear neutrophil-mediated inflammatory re-
sponses are critically important for maintaining host integrity. To
respond to tissue inflammation, PMN leave the circulation and
migrate into the inflamed site. By so doing they are exposed to
several external conditions known to affect their physical and
Fig. 3. Effect of interleukin-8 (IL-8) treatment
on spontaneous apoptosis was studied
employing DNA-fragmentation assay. Cells
were cultured in the absence and in the
presence of IL-8, or Groa (100 nM). Samples
were harvested after 20 hours, DNA was
extracted and 7.5 mg were electropheresed on
an 1.5% agarose gel. No DNA-fragmentation
was observed in freshly isolated PMN (lane 1),
whereas extensive fragmentation occurred in
untreated cells after 20 hours (lane 2). IL-8
(lane 3) and Groa (lane 4) inhibited DNA-
ladders. A typical example of two distinct
experiments is shown.
Fig. 4. Effect of interleukin-8 (IL-8) pretreatment on tumor necrosis
factor alpha (TNFa)-mediated apoptosis was studied. Polymorphonuclear
neutrophils (PMN) of the same preparation were first treated with either
vehicle (closed symbols) or with 50 nM IL-8 (open symbols) and challenged
with 20 ng/ml TNFa (N 5 5). Samples were harvested after four hours and
the percentage of apoptotic PMN was measured by flow cytometry.
Fig. 5. Effect of interleukin-8 (IL-8) and Groa on polymorphonuclear
neutrophil (PMN) apoptosis cultured for 20 hours was compared in
parallel. Cells of the same preparation were exposed to either IL-8 (f) or
Groa (M) at increasing concentrations: 1, 5, 10, 50, and 100 nM respec-
tively. Data are given as mean 6 SEM (N 5 7). Differences between IL-8
and Groa were significant at 50 nM and at 100 nM (*).
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functional states. These environmental signals include cell-cell
and cell-matrix interactions, as well as exposure to soluble sub-
stances such as cytokines. A variety of different cytokine effects on
PMN have been characterized. Recently, attention has been
directed towards cytokine-mediated effects on apoptosis. For
instance, GM-CSF, G-CSF, IL-1, IL-15, and interferon-g increase
PMN survival by delaying programmed cell death [20–22]. In
contrast, IL-6 and TNFa have been reported to accelerate
apoptosis [16, 23–25]. Polymorphonuclear neutrophil apoptosis is
important because it provides a signal for PMN removal [14], and
because it results in the loss of functional PMN responsiveness
[13]. Thus, modulation of apoptosis, either its delay or accelera-
tion, may have a major effect on the inflammatory process.
Several studies have demonstrated an association of various
diseases with the chemokine IL-8, such as rheumatoid arthritis
[26], adult respiratory distress syndrome [27, 28], psoriasis [29,
30], proliferative glomerulonephritis, [31] and primary systemic
vasculitis [32]. Interleukin-8 is produced by numerous cell types,
including endothelial cells, epithelial cells, fibroblasts, hepato-
cytes, mesangial cells, T-cells, monocytes, and even PMN [9, 33].
Moreover, PMN stimulated in vivo show increased IL-8 produc-
tion. Harvested from skin lesions on the forearm of volunteers,
PMN expressed 100-fold more and released 50-fold more IL-8
than freshly isolated cells from the same donor [34]. Interestingly,
PMN activation also induces release of proteolytic enzymes that
can enhance IL-8 production by endothelial cells [35]. The same
proteases cleave a longer form of IL-8, thereby generating a more
active shorter form [36]. These examples demonstrate that inflam-
mation creates an IL-8 rich milieu and that even PMN, once they
have arrived at inflammatory sites, can promote their own recruit-
ment.
Polymorphonuclear neutrophils have various response patterns
to IL-8 including shape change [37], degranulation [38], actin
polymerization [39], and up-regulation of adhesion molecules
[40]. Critically important for the inflammatory response is the
chemotactic effect of IL-8. The cytokine attracts PMN from the
circulation into sites of inflammation. Our findings characterize
an additional biological property of IL-8, namely, a delay of PMN
apoptosis. We demonstrated a clear dose- and time-dependent
inhibition of spontaneous apoptosis in culture. In contrast to our
study, two other studies employing IL-8 doses similar to ours
reported no modulation of PMN apoptosis. However, both studies
used longer incubation periods: 72 hours [21] and 48 to 96 hours
[20], respectively. The investigators did not study the early time
points, that is, the first 30 hours. We believe that these early time
points represent the greatest PMN activity in terms of killing and
the recruitment of other inflammatory cells. After 48 hours, PMN
activity may be less relevant than that of monocytes and other
invading cells.
Stimulated PMN release cytokines, including both TNFa and
IL-8 [9, 41]. The release process is interactive since endogenous
synthesis of TNFa in lipopolysaccharide-treated PMN can en-
hance IL-8 generation in an autocrine/paracrine manner [41]. We
and others have shown that TNFa can rapidly accelerate PMN
Fig. 6. Detection of Bcl-2 proto-oncogene by RT-PCR. RNA was purified from HL-60 cells or from PMN. First, strand cDNA was generated by reverse
transcription, amplified by PCR, and electropheresed on 1.8% Metaphor gel. The upper band corresponds to G3PDH and the lower band to Bcl-2. Bcl-2
mRNA was not expressed in freshly isolated PMN (lane 1) but was detected in HL-60 (lane 2). Incubation of PMN in the absence or in the presence
of IL-8 (10 nM, and 100 nM) for 20 hours did not result in up-regulation of Bcl-2 (lanes 3, 4, 5).
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apoptosis within two hours of treatment [16, 24, 25]. In this study,
we demonstrated that IL-8 not only inhibits spontaneous apopto-
sis but also counteracts TNFa-mediated apoptosis. Because of the
fact that apoptotic PMN have a decreased capability to respond to
activating stimuli, as shown for FMLP and opsonized zymosan
[13], delaying apoptosis would lead to accumulation of cells still
capable of responding properly. In that way, IL-8 may prolong and
amplify PMN-related effects.
We believe that our results demonstrating a delay of PMN
apoptosis by IL-8 could be relevant to inflammatory renal dis-
eases. For instance, in a recently described rat model of immune
complex-mediated glomerulonephritis, PMN-apoptosis was iden-
tified as one of the mechanisms involved in restoring PMN to
basal activity [42]. Interestingly, IL-8 is present both in urine and
in renal tissue in patients with glomerulonephritis and could be a
modulator of PMN apoptosis in this setting [31]. Finally, recent in
vitro data indicate that PMN apoptosis is important in the
presentation of target antigens for ANCA [43]. Since increased
levels of IL-8 are found in active ANCA-vasculitis [44, 45], an
effect of IL-8 on PMN apoptosis could be of importance.
We examined the two IL-8 receptors, RI and RII, in terms of
modulating apoptosis. Both receptor types bind to IL-8 with high
affinity. Interleukin-8 RII, but not RI, binds to other members of
the CXC-cytokine family, such as Groa. The fact that IL-8
treatment resulted in a stronger effect on apoptosis than Groa
should not have been surprising. Interleukin-8 exposure also
results in increased CD11b expression, enhanced phospholipase
D activation, intracellular calcium surge, and accelerated chemo-
taxis, compared to Groa [17, 18]. The results show that the IL-8
RII is capable of delaying apoptosis in any event. The additional
occupation of IL-8 RI, as is the case with IL-8 administration, may
provide an additive effect.
The Bcl-2 protooncogene encodes a protein shown to block
programmed cell death [46, 47]. While Bcl-2 has been detected in
a variety of cell types, it is not expressed in freshly isolated resting
human PMN [48, 49]. This lack of expression may be responsible
for the very short lifespan of PMN. We looked for Bcl-2 protein
and for Bcl-2 gene expression in IL-8 treated cells and found
neither. Thus, we conclude that IL-8 must inhibit apoptosis by
Bcl-2-independent mechanisms. The nature of these mechanism
remains to be elucidated. Numerous possibilities exist; inhibition
of interleukin I converting enzyme (ICE) and ICE-like proteases
is one example.
In summary, human PMN undergo spontaneous apoptosis in
vitro. Treatment with the proinflammatory cytokine TNFa results
in rapid acceleration of programmed cell death. The chemoattrac-
tant cytokine, IL-8, delays spontaneous as well as TNFa-mediated
apoptosis in vitro. The IL-8 receptor II is capable of mediating the
signal, although the IL-8 receptor I may provide an added
response. The effect on apoptosis is independent of Bcl-2. Our
data suggest that IL-8 delays the removal of PMN by inhibiting
programmed cell death. The number of functionally intact PMN
at sites of inflammation could thereby be enhanced. This mecha-
nism may be of importance for a controlled and effective inflam-
matory response.
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